ISOXSUPRINE HYDROCHLORIDE- isoxsuprine hydrochloride tablet
ECI Pharmaceuticals LLC
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
----------
Isoxsuprine Hydrochloride Tablets, USP
DESCRIPTION
Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with the following chemical structure:
 |
| C
18H
23NO
3 ∙ HCl
p-Hydroxy-α[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol hydrochloride. |
Quantitative Ingredient Information: Each tablet taken orally contains 10 or 20 mg Isoxsuprine HCl
Pharmacological Class: Peripheral Vasodilator
INDICATIONS
Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows:
Possibly Effective
- For the relief of symptoms associated with cerebrovascular insufficiency.
- In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease.
Final classification of the less-than-effective indications requires further investigation.
CONTRAINDICATIONS
There are no known contraindications to oral use when administered in recommended doses.
Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.
ADVERSE REACTIONS
On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.
Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted.
Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride have been used to inhibit pre-term labor.
Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received Isoxsuprine Hydrochloride. Pulmonary edema has been reported in mothers treated with beta stimulants. Isoxsuprine Hydrochloride is neither approved nor recommended for use in the treatment of premature labor.
HOW SUPPLIED
Isoxsuprine HCl Tablets, USP 10 mg are white, round, biconvex tablets identified as "I10" debossed on one side and bisected on the other.
| Bottle of 100 | NDC 51293-606-01 |
| Bottle of 1000 | NDC 51293-606-10 |
Isoxsuprine HCl Tablets, USP 20 mg are white, round, biconvex tablets identified as "20" debossed on one side and bisected on the other.
| Bottle of 100 | NDC 51293-605-01 |
| Bottle of 1000 | NDC 51293-605-10 |
COMPOSITION
Isoxsuprine HCl Tablets, 10 mg and 20 mg. These tablets contain the following Inactive Ingredients: Corn Starch, Lactose Monohydrate, Magnesium Stearate (Vegetable), Microcrystalline Cellulose.
| ISOXSUPRINE HYDROCHLORIDE
isoxsuprine hydrochloride tablet |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| ISOXSUPRINE HYDROCHLORIDE
isoxsuprine hydrochloride tablet |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - ECI Pharmaceuticals LLC (962476029) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| ECI Pharmaceuticals LLC | 962476029 | manufacture(51293-605, 51293-606) | |